Clinical trial results from testing focused ultrasound-induced blood-brain barrier opening with drug delivery in patients with Alzheimer’s disease were published in the New England Journal of Medicine.
Data from the first three participants suggested that the procedure was safe, and there was a measurable reduction of amyloid-beta.
In a recent editorial in the New England Journal of Medicine, Kullervo Hynynen, PhD, describes how focused ultrasound is being used to open the blood-brain barrier.
Read his eloquent description of the science behind the Alzheimer’s disease clinical trial data that were recently published in the journal.
Mishal Mendiratta-Lala, MD, is an abdominal and cross-sectional interventional radiologist at the University of Michigan who led the US liver tumor histotripsy clinical trial (#HOPE4LIVER).
She describes her preclinical and clinical research and plans to continue using histotripsy to treat patients with liver cancer.
“The Alzheimer’s disease study builds on a growing body of laboratory studies and clinical trials – much of which were funded by the Foundation – and we look forward to additional research that will lead to slowing disease progression and improving cognition in these patients.”